Tavokinogene telsaplasmid - OncoSec Medical

Drug Profile

Tavokinogene telsaplasmid - OncoSec Medical

Alternative Names: DNA IL-12; IL-12 gene therapy; IL-12 plasmid; ImmunoPulse; ImmunoPulse®IL-12; Interleukin-12 gene therapy; intratumoral pIL-12-EP; LipoVIL12; OMS ElectroImmunotherapy™; pIL-12; pIL-12 Electroporation; Tavo; tavo-EP

Latest Information Update: 13 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inovio Biomedical Corporation
  • Developer Fred Hutchinson Cancer Research Center; Massachusetts General Hospital; Merck Sharp & Dohme; OncoSec Medical; University of California at San Francisco; University of Washington
  • Class Antineoplastics; Cytokine genes; Gene therapies; Immunotherapies; Interleukins
  • Mechanism of Action Gene transference; Immunomodulators; Interleukin-12 expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Malignant melanoma
  • New Molecular Entity No
  • Available For Licensing Yes - Malignant melanoma

Highest Development Phases

  • Phase II Breast cancer; Cutaneous T cell lymphoma; Head and neck cancer; Malignant melanoma; Merkel cell carcinoma
  • Preclinical Solid tumours

Most Recent Events

  • 06 Aug 2018 OncoSec enters into a research collaboration agreement with the University of California, Los Angeles for Malignant melanoma (Combination therapy, Second-line therapy or greater)
  • 06 Aug 2018 Phase-II clinical trials in Breast cancer (Combination therapy, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater) in USA (Intratumoural)(9246616; NCT03567720)
  • 17 Jul 2018 OncoSec Medical plans the phase II KEYNOTE-890 trial for Breast cancer (Combination therapy, Late-stage disease, Metastatic disease, Inoperable/Unresectable, Second-line therapy or greater) in the third quarter of 2018 (Intratumoural) (NCT03567720)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top